Keyphrases
Beta-blockers
28%
Chronic Kidney Disease
42%
Cost Reduction
14%
Dapagliflozin
14%
Electronic Health Record Data
14%
Event Rate
14%
First Hospitalization
14%
First Year
14%
Guideline Implementation
14%
Guideline-directed Medical Therapy
71%
Health Care Costs
28%
Health Claims Data
14%
Heart Disease Diagnosis
14%
Heart Failure
100%
Heart Failure Hospitalization
100%
Heart Failure Patients
14%
Hospital Care
14%
Hospital Costs
14%
Japan
14%
Kaplan-Meier Estimator
14%
Longitudinal Cohort Study
14%
Managing Risk
14%
Medicine Costs
100%
Medicine Use
100%
Mineralocorticoid Receptor Antagonists
28%
Mortality Outcomes
100%
Myocardial Infarction
28%
Outcome Costs
100%
Peripheral Arterial Disease
28%
Primary Diagnosis
14%
Rehospitalization
71%
Renin-angiotensin System Inhibitors
28%
Risk Cost
14%
Sacubitril-valsartan
28%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
28%
Sweden
14%
United Kingdom
14%
United States
14%
Medicine and Dentistry
Apoplexy
18%
Arteriosclerosis Obliterans
18%
Beta Adrenergic Receptor Blocking Agent
18%
Chronic Kidney Disease
27%
Cohort Analysis
9%
Combination Therapy
45%
Congestive Heart Failure
100%
Dapagliflozin
9%
Electronic Health Record
9%
Health Care Cost
100%
Kaplan Meier Method
9%
Medicine
100%
Mineralocorticoid Antagonist
18%
Myocardial Infarction
18%
Observational Study
9%
Renin-Angiotensin System Inhibitor
18%
Sacubitril
18%
Secondary Data
9%
Sodium Glucose Cotransporter 2 Inhibitor
18%
Valsartan
18%
Pharmacology, Toxicology and Pharmaceutical Science
Beta Adrenergic Receptor Blocking Agent
16%
Cerebrovascular Accident
16%
Chronic Kidney Failure
25%
Cohort Study
8%
Combination Therapy
41%
Congestive Heart Failure
100%
Dapagliflozin
8%
Heart Infarction
16%
Mineralocorticoid Antagonist
16%
Observational Study
8%
Peripheral Occlusive Artery Disease
16%
Renin-Angiotensin System Inhibitor
16%
Sodium Glucose Cotransporter 2 Inhibitor
16%
Valsartan/Sacubitril
16%